Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.